Cargando…

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors

PURPOSE: Acromegaly and neuroendocrine tumors are rare diseases that, under certain conditions, can be treated with somatostatin analogs. The aim was to determine the prescription patterns of somatostatin analogs in a group of patients with acromegaly and neuroendocrine tumors affiliated with the Co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Machado-Alba, J. E., Machado-Duque, M. E., Gaviria-Mendoza, A., Arsof-Saab, I. N., Castellanos-Moreno, C. A., Botero, L., Triana, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829641/ https://www.ncbi.nlm.nih.gov/pubmed/35913681 http://dx.doi.org/10.1007/s40618-022-01875-7

Ejemplares similares

Prescription patterns of long-acting somatostatin analogues
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2017)

Lipid-lowering drug prescriptions in a group of Colombian patients
por: Gaviria-Mendoza, Andrés, et al.
Publicado: (2019)

Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study
por: Berton, Alessandro Maria, et al.
Publicado: (2022)

Patterns of Antibiotic Prescription in Colombia: Are There Differences between Capital Cities and Municipalities?
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2020)

Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
por: Cella, David, et al.
Publicado: (2021)

Antibiotic Prescriptions for Respiratory Tract Viral Infections in the Colombian Population
por: Machado-Duque, Manuel E., et al.
Publicado: (2021)

Acromegaly: Pathophysiological Considerations and Treatment Options Including the Evolving Role of Oral Somatostatin Analogs
por: Daniel, Charles P., et al.
Publicado: (2023)

Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review
por: Heidarpour, Maryam, et al.
Publicado: (2019)

PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly
por: O’Toole, Dermot, et al.
Publicado: (2022)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Evaluation of Treatment Patterns and Direct Costs Associated with the Management of Neuropathic Pain
por: Machado-Duque, Manuel E, et al.
Publicado: (2020)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis
por: Gurel, Michelle H., et al.
Publicado: (2017)

Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives
por: Baldelli, Roberto, et al.
Publicado: (2014)

Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature
por: Kizilgul, Muhammed, et al.
Publicado: (2022)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

The Future of Somatostatin Receptor Ligands in Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2021)

Real-World Effectiveness of Therapy With Rosuvastatin Combined With Fenofibric Acid in a Sample of Colombian Patients With Mixed Dyslipidemia
por: Machado-Duque, Manuel E., et al.
Publicado: (2020)

E‐cadherin expression is associated with somatostatin analogue response in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2019)

Place of Preoperative Treatment of Acromegaly with Somatostatin Analog on Surgical Outcome: A Systematic Review and Meta-Analysis
por: Pita-Gutierrez, Francisco, et al.
Publicado: (2013)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Glycemic profile in patients with acromegaly treated with somatostatin analogue
por: Valea, A, et al.
Publicado: (2015)

Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
por: Darden, Christina, et al.
Publicado: (2021)

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine
por: Ehsanullah, Syed, et al.
Publicado: (2022)

Indication-prescription study for the management of conjunctivitis in a Colombian population
por: Valladales-Restrepo, Luis Fernando, et al.
Publicado: (2022)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
por: Chin, Sang Ouk, et al.
Publicado: (2019)

Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly
por: Kontogeorgos, George, et al.
Publicado: (2022)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
por: Daly, Adrian F, et al.
Publicado: (2019)

Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs
por: Li, Su-Chen, et al.
Publicado: (2015)

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals
por: Ortendahl, Jesse D, et al.
Publicado: (2017)

(225)Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic
por: Rubira, Léa, et al.
Publicado: (2023)

Real-World Evidence: Pharmacoepidemiology for Daily Clinical Practice—An Experience from Colombia
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2020)

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

PMON57 Impact of Injection Modalities on Real-World Injection Experience in Patients with Acromegaly or Neuroendocrine Tumors (NETs) Treated With Somatostatin Analog (SSA) Therapy: Data from the PRESTO 2 Survey
por: Ribeiro-Oliveira, Antonio, et al.
Publicado: (2022)

Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
por: Sala, E., et al.
Publicado: (2021)

Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
por: Gil, Joan, et al.
Publicado: (2021)

Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs
por: Fernandes, Isabel, et al.
Publicado: (2012)

Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors
por: Fotouhi, Omid, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mdmo7b24n83gtg25fuuv1oktb0